Koski Comments on Prospects for Prescription Drug Legislation

26 April 2018 Pharmaceutical Technology News
Partner Katy Koski was quoted in a Pharmaceutical Technology article, “CREATES Act Dropped But May Still See Progress,” about the chances that legislation aimed at lowering the costs of prescription drugs will be taken up by Congress this year.

The legislation, formally known as the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, would prevent companies making branded drugs from refusing to sell samples to firms producing lower-cost generic and biosimilar versions, who need access to branded drugs to conduct the comparative testing required to get their own versions approved.

Koski said the focus on the sample-access issue has increased significantly with the introduction of biosimilars, whose manufacturers need to buy multiple batches of branded drugs from various manufacturing lots.

Related Services

Insights

Lacktman, Ferrante Cited in mHealth Intelligence About Ryan Haight Act
19 September 2019
mHealth Intelligence
Tinnen Discusses How Viewpoint Diversity Helps Businesses Thrive
18 September 2019
InsideTrack
Vernaglia Comments on AHA v Azar Decision
18 September 2019
MedPage Today
Lach Comments on Launch of New Group
16 September 2019
BizTimes Milwaukee
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.